Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (a...

2023-11-08 08:30 1900

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-11-01 08:30 1559

Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting

SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-09-28 08:30 1973

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenici...

2023-09-21 18:05 2108

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2023-08-25 19:37 2346

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercializatio...

2023-08-11 08:00 2857

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusiv...

2023-07-18 08:30 2305

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has ...

2023-07-17 08:30 2697

Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma

- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor...

2023-06-01 10:09 3220

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 mo...

2023-05-26 09:41 3073

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-05-23 17:25 2655

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibod...

2023-05-18 11:53 3079

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody...

2023-05-18 02:47 2744

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-05-17 08:30 2909

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-04-27 08:30 2886

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-0...

2023-04-17 20:22 2266

Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia

* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugat...

2023-03-29 08:30 2449

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation

SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-03-28 21:40 2492

Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

– Five posters will showcase progress with multiple preclinical and clinical programs, including t...

2023-03-20 15:20 1988

Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate...

2023-03-14 12:29 2623